Want to see TSE:BETR full AI Analyst Report?
BETR Stock Chart & Stats
C$0.37
C$0.03(14.29%)
At close: 4:00 PM EDT
C$0.37
C$0.03(14.29%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.46
Previous CloseN/A
Volume348.32K
Average Volume (3M)353.53K
Market Cap
C$154.50M
Enterprise ValueC$51.90M
Total Cash (Recent Filing)C$973.59K
Total Debt (Recent Filing)C$2.51M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Dec 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding618,007,200
10 Day Avg. Volume413,283
30 Day Avg. Volume353,532
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-0.75
Price to Sales (P/S)0.00
P/FCF Ratio-11.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.19
Revenue Forecast (FY)C$2.99B
Bulls Say, Bears Say
Bulls Say
Pipeline FocusConcentrating on mental-health and neurological drug candidates gives the company a defined therapeutic focus and a pathway to create value through clinical development. If pipeline programs progress, associated intellectual property and clinical milestones could support future partnering or commercialization opportunities.
Narrowing LossesThe substantial reduction in losses compared with 2022 indicates improved cost discipline or lower development spending intensity. Although the company remains unprofitable, a smaller loss base can extend available resources and make future financing needs more manageable if operating trends continue.
Improved Cash DisciplineImprovement in operating and free-cash-flow performance suggests tighter spending control relative to earlier periods. This does not make the business self-funding, but continued moderation of cash burn could preserve development capacity and reduce the pace at which external capital is required.
Bears Say
No RevenueThe absence of reported revenue means the company has not yet demonstrated commercial product traction or an internally generated funding stream. Its ability to finance research, clinical development, and other operations therefore remains dependent on future commercialization or external capital.
Negative EquityA persistent equity deficit weakens financial flexibility and raises solvency risk, even though total debt is modest in absolute terms. Negative equity can also constrain financing choices and make it harder to fund pipeline development without dilution or other costly capital arrangements.
Ongoing Cash BurnConsistently negative operating and free cash flow shows that current activities do not fund themselves. Continued cash consumption could force additional financing before commercial revenue arrives, creating funding uncertainty and potentially limiting the pace or scope of pipeline investment.
BetterLife Pharma News
BETR FAQ
What was BetterLife Pharma’s price range in the past 12 months?
BetterLife Pharma lowest stock price was C$0.04 and its highest was C$0.46 in the past 12 months.
What is BetterLife Pharma’s market cap?
BetterLife Pharma’s market cap is C$154.50M.
When is BetterLife Pharma’s upcoming earnings report date?
BetterLife Pharma’s upcoming earnings report date is Dec 17, 2026 which is in 46 days.
How were BetterLife Pharma’s earnings last quarter?
BetterLife Pharma released its earnings results on Sep 29, 2026. The company reported -C$0.013 earnings per share for the quarter.
Is BetterLife Pharma overvalued?
According to Wall Street analysts BetterLife Pharma’s price is currently Overvalued.
Does BetterLife Pharma pay dividends?
BetterLife Pharma does not currently pay dividends.
What is BetterLife Pharma’s EPS estimate?
BetterLife Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BetterLife Pharma have?
BetterLife Pharma has 618,007,200 shares outstanding.
What happened to BetterLife Pharma’s price movement after its last earnings report?
BetterLife Pharma reported an EPS of -C$0.013 in its last earnings report. Following the earnings report the stock price went up 21.053%.
Which hedge fund is a major shareholder of BetterLife Pharma?
Currently, no hedge funds are holding shares in TSE:BETR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BetterLife Pharma
BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-based technologies, designed to engage the immune system in combating viral infections. Its active development pipeline includes BETR-001, intended for major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another key asset, BETR-002, is being advanced to address benzodiazepine dependency, anxiety, and spasticity. Further in development are MM-003 for COVID-19 and other respiratory viral infections; MM-001, a topical intravaginal cream for HPV-induced cervical intraepithelial neoplasia; and AP-002, designated for cancer treatment. BetterLife Pharma Inc. maintains a research collaboration with the University of California San Diego, focusing on preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. Headquartered in Vancouver, Canada, the company was founded in 2002 and was formerly known as Pivot Pharmaceuticals Inc. before adopting the name BetterLife Pharma Inc. in December 2019.
Technical Analysis
COSCIENS Biopharma
―
PharmaTher Holdings Ltd
―
Marvel Biosciences Corp
―
Doseology Sciences
―
PharmAla Biotech Holdings, Inc.
―